RXSIGHT, INC.
Last · NasdaqGM$4.52-0.01 (-0.22%)close · yahoo · 17h ago
Market cap$188.00M41.6M sh
P/E · TTM-4.2fwd -6.6 · eps -1.14 · loss
Beta1.14vs S&P 500
Div yield0.00%annual · TTM
52w range
$4.40$13.22
Volume826.7Ksession
| Revenue | $127.6M |
|---|---|
| Operating income | $-31.6M |
| Net income | $-28.0M |
| Free cash flow | $-23.1M |
| Operating margin | -24.8% |
| Net margin | -21.9% |
| Return on equity | -10.6% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-25
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Sbc Revenue Elevated
- Accumulated Deficit High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -29.0%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -11.5%
- Cash Runway Low — Cash runway ~1.3 years
- Sbc Revenue Elevated — SBC/Revenue 23.5%
- Accumulated Deficit High — Accumulated deficit / equity 240%
Upcoming earnings
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.19
Est. revenue
27.2M
Earnings transcripts
Press & signals
- GlobeNewswire
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
- GlobeNewswire
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
- GlobeNewswire
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans